FOR IMMEDIATE RELEASE
March 29, 2021
Tracey L. Mancini
Marketing Communications Manager
PHILLIPS LYTLE LLP PARTNERS DOUGLAS W. DIMITROFF AND LISA L. SMITH NAMED TO LAW360 EDITORIAL ADVISORY BOARDS
Buffalo, N.Y. – Phillips Lytle LLP Partners Douglas W. Dimitroff and Lisa L. Smith have been selected for 2021 Law360 Editorial Advisory Boards. Mr. Dimitroff has been named to the Telecommunications Editorial Advisory Board, and Ms. Smith has been selected to the Life Sciences Editorial Advisory Board.
The purpose of the editorial advisory boards is to provide insight to Law360 on trends in legal developments. Hundreds of lawyers contribute thought leadership to Law360, but only a limited number are chosen for editorial advisory boards.
Mr. Dimitroff will participate in the Telecommunications Editorial Advisory Board for the second consecutive year. Focusing in the areas of telecommunications law and commercial real estate, he has over 25 years of experience in telecommunications matters, representing leading telecommunications carriers, infrastructure providers and numerous other clients involved in the telecommunications industry. His representation has included transactional and litigation matters – such as permitting for wireless telecommunication carriers, tower owners and developers – and site leasing work, site development, and asset sales and purchases throughout the U.S. He has particular expertise in distributed antenna system (DAS) and other small cell networks, where he is involved with both business and regulatory aspects. Mr. Dimitroff is a board member and founder of the New York State Wireless Association.
Ms. Smith is co-leader of the Phillips Lytle Life Sciences & Health Effects Practice Team. She has more than 30 years of life sciences litigation experience focusing on high-stakes product liability litigation in class action and MDL settings, and national coordination of the scientific defenses to claims regarding drugs and devices. She has been at the forefront of cutting edge issues in defending drug and medical device manufacturers in complex litigation and regulatory compliance matters.